JAK2 and psoriasis: In a phase 1 trial, brepocitinib was well tolerated by both healthy volunteers and patients with psoriasis, but decreases in platelet and reticulocyte counts occasionally occurred and have been accounted for by some degree of Jak2 inhibition [10,48].